1588-A4 (ARS-1620 Intermediate) 是 ARS-1620 的中间体，ARS-1620 是一种具有理想药代动力学的阻转异构选择性 KRASG12C 抑制剂。

DT-061 is an orally bioavailable protein phosphatase 2A (PP2A) activator. It could be applied in the therapy of KRAS-mutant and MYC-driven tumorigenesis.

RMC5127是一种口服和突变选择性的RAS G12V抑制剂，先与亲环蛋白A(CypA)形成复合物，然后和RAS G12V（ON）形成三元复合物并且抑制，具有中枢神经系统（CNS）渗透性和脑渗透性。RMC-5127在KRAS G12V突变癌细胞中能够抑制RAS通路和诱导凋亡，具有抗肿瘤活性。

Braftide 是一种BRAF激酶变构抑制剂，作用于BRAF激酶二聚体表面，抑制其形成。Braftide 对野生型BRAF和致癌型BRAFG469A的IC50分别为364 nM和172 nM。结合TAT序列后，Braftide 可以抑制MAPK信号通路，阻止KRAS突变肿瘤细胞的增殖（对于HCT116和HCT-15，EC50分别为7.1 μM和6.6 μM）。

Deltasonamide is a potent and selective inhibitor of PDE6δ‐KRas.

FGTI-2734 mesylate, a RAS C-terminal mimetic compound with dual farnesyl transferase (FT) and geranylgeranyl transferase-1 (GGT) inhibitory activities (IC50s of 250 nM and 520 nM for FT and GGT, respectively), mitigates KRAS resistance by preventing its membrane localization, effectively impeding mutant KRAS patient-derived pancreatic tumors.